Tyler Liban

机构：Ansun BioPharma (United States) · ORCID：0000-0001-8793-8584

发表论文 151 篇 · 总被引 419 次 · h-index 7

代表论文

• A novel anti-LAG-3/TIGIT bispecific antibody exhibits potent anti-tumor efficacy in mouse models as monotherapy or in combination with PD-1 antibody (2024 · Scientific Reports · 被引 15)
• Structurally related but genetically unrelated antibody lineages converge on an immunodominant HIV-1 Env neutralizing determinant following trimer immunization (2021 · PLoS Pathogens · 被引 9)
• Abstract 6368: Preclinical pharmacology and safety studies of ZG005: an anti-PD-1/TIGIT bispecific mAb in a phase I clinical trial for advanced tumors (2023 · Cancer Research · 被引 3)
• ZGGS15, a Novel IgG4 Bispecific Monoclonal Antibody Targeting Both LAG-3 and Tigit, Demonstrates Outstanding Anti-Tumor Activity and Can be Used As Monotherapy or in Combination with Anti-PD-1 Antibodies for Cancer Immunotherapy (2023 · Blood · 被引 1)
• Structurally related but genetically unrelated antibody lineages converge on an immunodominant HIV-1 Env neutralizing determinant following trimer immunization (2021 · bioRxiv (Cold Spring Harbor Laboratory) · 被引 1)
• Abstract 2323: ZGGS18, a bispecific drug candidate of anti-VEGF and TGFbeta-trap, inhibiting tumor proliferation and improving tumor microenvironment with I/O therapy (2023 · Cancer Research)